Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X by Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, adding:
“What’s also interesting here is there are essentially 4 trials asking the same question regarding: adjuvant IO in ‘high risk’ HCC.
And if just 1 is positive (and for surrogate RFS endpoint), IO will be approved in spite of all the other negative data.”
Quoting Mark Yarchoan‘s post:
“More disappointing news in HCC:
Adjuvant pembrolizumab failed to beat surveillance in the global P3 KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after IMbrave050.”
More posts featuring Nina Niu Sanford and Mark Yarchoan on OncoDaily.